Erasca lays off 18% while swapping out KRAS program for fresh anti-tumor options

Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets while clearing space in its own pipeline and laying off 18% of its employees in the process.